Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Opendoor Technologies Inc (OPEN) Price & Performance

Bio-Rad Laboratories, Inc. Class A Common StockTrade
Opendoor Technologies IncTrade

Price performance (Past 24H)

Key statistics

Bio-Rad Laboratories, Inc. Class A Common Stock vs Opendoor Technologies Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Opendoor Technologies Inc trades at $4.56 (market cap $4.39B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is the larger of the two by market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Opendoor Technologies Inc nearer its low. Which is the better fit depends on your goals.

BIOOPEN
Market Cap
$8.04B$4.39B
Sector
HealthReal Estate
52-Week High
$339.75$10.52
52-Week Low
$241.71$1.04
Enterprise Value
$7.85B$4.73B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bio-Rad Laboratories, Inc. Class A Common Stock

BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.

Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.

Opendoor Technologies Inc

Opendoor (OPEN) trades at $4.485, down 5.86% today, reflecting ongoing volatility amid a challenging housing market. The stock shows a bearish technical trend with support near $4 and resistance at $5. Fundamentally, the company reported a net loss of $1.30 billion on $4.37 billion revenue in 2025, with a negative net margin of 35.25%. Recent news highlights CEO leadership and a shift toward AI, including the closure of India operations affecting 250 employees (Reuters, 2026-06-11).

The outlook remains cautious due to persistent losses and high debt, though the low P/S ratio of 0.94 offers some valuation appeal. Risks include execution of the new business model, interest rate sensitivity, and competitive pressure. Analyst sentiment is mixed with 65.39% hold ratings, indicating wait-and-see approach until sustained profitability emerges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO

About Opendoor Technologies Inc

Opendoor Technologies Inc is a digital platform for residential real estate. This platform enables customers to buy and sell houses online. It generates revenue through home sales, along with other revenue from real estate services.

Read more on OPEN